The Centers for Medicare and Medicaid Services (CMS) has proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor (CAR) T-cell therapies as part of the proposed 2021 Inpatient Prospective Payment System (IPPS), which determines Medicare payment policies. The new approach would compensate health-care systems that administer CAR T-cell treatments based on the average price of the therapies currently on the market: Gilead’s axicabtagene ciloleucel and Novartis’ tisagenlecleucel.
Medicare reimbursement rates for CAR T-cell therapies are currently based on the average cost of administering a bone marrow transplant. A 2017 study found the median cost for these transplant procedures was between $150,000 and $300,000, depending on the patients’ diagnosis. These costs are lower than those of CAR T-cell treatments, which have list prices upwards of $400,000 per patient. The previous reimbursement system may have forced hospitals to choose between taking a financial loss or declining to offer the treatment.
The new rules would only affect patients who receive coverage through Medicare, but private insurance providers may use federal guidelines as a model for setting their own payment rates.
CMS is expected to confirm the IPPS rulings in the fall after accepting comments from the public and industry and patient groups.